Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

HNRNPL and its RNA Targets in Prostate Cancer

ABSTRACT: HNRNPL and its RNA Targets in Prostate Cancer

PROVIDER: PRJNA295180 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR2318170_1.fastq.gz	Fastqsanger.gz
	SRR2318170_2.fastq.gz	Fastqsanger.gz
	SRR2318161.fastq.gz	Fastqsanger.gz
	SRR2318171_1.fastq.gz	Fastqsanger.gz
	SRR2318171_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 37

Similar Datasets

Regulartory effect of HNRNPL and LARP on RNA expression in LNCaP prostate cancer cells

Project description:Analysis of RNA expression in LNCaP prostate cancer cells treated with different siRNAs to define the regulatory effect of HNRNPL and LARP on RNA expression.

2017-09-28 | GSE72842 | GEO

Regulartory effect of HNRNPL and LARP on circular RNA expression in LNCaP prostate cancer cells

Project description:Analysis of circular RNA expression in LNCaP prostate cancer cells treated with different siRNAs to define the regulatory effect of HNRNPL and LARP on circular RNA expression.

2017-09-28 | GSE72840 | GEO

HNRNPL RIP-seq in LNCaP prostate cancer cells

Project description:RNA immunoprecipitation coupled with next generation sequencing (RIP-seq) was used to map the HNRNPL-RNA interactome in LNCaP cells.

2016-12-28 | GSE72841 | GEO

NTRAS hnRNPL RNA sequencing in HUVECs

Project description:In the current project with aim to unequivocally characterize a novel splicing-regulatory network that proves to be a central mediator of endothelial barrier function and vascular integrity. At the core of this network is the endothelial enriched lncRNA NTRAS (annotated as RP11-354k1.1) is shown to control alternative splicing decisions in HUVECs through interplaying with splicing factor hnRNPL. Specifically, in the project we show that NTRAS sequesters the splicing factor hnRNPL through a CA dinucleotide motif, to enhance TJP1 exon 20 usage, thereby TJP1α+ isoform. In turn disrupting TJP1α+ isoform expression impaired endothelial barrier function. Collectively, this splicing-regulatory network might prove fundamental in unlocking new interventions strategic to prevent or reverse vascular leakage.

2022-01-10 | E-MTAB-11311 | biostudies-arrayexpress

AR-V7 targets the oncogenic genes in castration resistant prostate cancer. [RNA]

Project description:AR-V7 targets the oncogenic genes in castration resistant prostate cancer. [RNA]

| PRJNA506948 | ENA

NTRAS hnRNPL RNA sequencing in HUVECs

Project description:NTRAS hnRNPL RNA sequencing in HUVECs

| PRJEB49865 | ENA

Long Noncoding RNA uc.345 promotes tumorigenesis of pancreatic cancer by upregulation of hnRNPL expression

Project description:Increasing evidence points to an important functional or regulatory role of long noncoding RNA in cellular processes as well as some cancer diseases result from the aberrant lncRNA expression. LncRNA could participate in the cancer progross and develop a significant role through the interaction with proteins. In the present study, we report a lncRNA termed uc.345 that is up-regulated in tumor tissues, compared to the corresponding noncancerous tissues. We found that a higher uc.345 expression lever was significantly more frequent in tissues with increased depth of invasion and advanced TNM tumor node metastasis T stage. Moreover, uc.345 serves as an independent risk factor for pancreatic cancer patients’ overall survival (OS). Through soft agar assay and tumor xenograft model, our results indicate that uc.345 could stimulate tumor growth in vitro and in vivo. We also found the uc.345 could upregulate the hnRNPL protein level, furthermore, we demonstrate that the inhibition of (hnRNPL) by its association with uc.345 contributes to depress tumorgenesis in vitro. Collectively, these results demonstrate that uc.345 functions as an oncogenic lncRNA that promotes tumor progression and serves as a poor predictor for pancreatic cancer patients' overall survival.

2016-09-06 | GSE86436 | GEO

HNRNPL and its RNA Targets in Prostate Cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2016-12-31 | GSE72844 | GEO

Multi-omic profiling reveals an RNA processing rheostat that predisposes to prostate cancer

Project description:Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer deaths in men. GWAS studies have identified variants associated with prostate cancer susceptibility, however, mechanistic and functional validation of these mutations are lacking. Mitochondrial energy metabolism plays an important role in the onset and development of cancer. A missense variant was identified in the ELAC2 gene, which encodes a dually localized nuclear and mitochondrial RNA processing enzyme, with predicted impact on metabolism and tumorigenesis. We used CRISPR/Cas9 genome editing to introduce this variant into the mouse Elac2 gene as well as to generate a prostate-specific gene knockout of Elac2. The mutations caused enlargement and inflammation in the prostate and nodule formation. Multi-omic profiling revealed defects in RNA and energy metabolism that activated proinflammatory and tumorigenic pathways as a consequence of impaired processing of mitochondrial and nuclear encoded non-coding RNAs and reduced protein synthesis. The Elac2 variant or knockout mice on the background of the transgenic adenocarcinoma of the mouse prostate (TRAMP) model show that Elac2 mutation with a secondary genetic insult exacerbated the onset and progression of prostate cancer and led to metastasis. Our systems biology analyses reveal a miRNA-mediated molecular mechanism by which specific non-coding RNAs elicit metabolic changes that drive prostate tumorigenesis and metastasis. We conclude that the ELAC2 variant is a predisposing factor for prostate cancer and provide a detailed molecular mechanism and physiologically relevant models of this cancer.

2023-04-19 | PXD033891 | Pride

RNA-Seq reveals novel mechanistic targets of withaferin A (WA) in prostate cancer cells

Project description:RNA-Seq analysis using WA-treated 22Rv1 human prostate cancer cells revealed upregulation and downregulation of 6993 and 6607 genes, respectively when compared to the vehicle-treated control. The pathways with significantly upregulated gene expression following WA treatment included mitogen-activated protein kinases, focal adhesion, endocytosis, and autophagy as revealed by KEGG and gene ontology analyses. WA treatment also resulted in downregulation of genes associated with metabolic pathways, oxidative phosphorylation, tricarboxylic acid cycle, cell cycle, and base excision repair. This study identifies novel mechanistic targets of WA in prostate cancer.

2019-09-17 | GSE137519 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data